Swiss National Bank
KLRS

Swiss National Bank’s Kalaris Therapeutics KLRS Stock Holding History

Swiss National Bank’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,883
Closed -$241K – 2614
2023
Q3 		$241K Sell
4,883
-495
-9% -$33.7K ﹤0.01% 2596
2023
Q2 		$421K Buy
5,378
+1,004
+23% +$95.4K ﹤0.01% 2564
2023
Q1 		$396K Sell
4,374
-509
-10% -$64.8K ﹤0.01% 2573
2022
Q4 		$576K Buy
4,883
+126
+3% +$21.4K ﹤0.01% 2540
2022
Q3 		$863K Buy
4,757
+1,409
+42% +$220K ﹤0.01% 2405
2022
Q2 		$300K Sell
3,348
-339
-9% -$35.5K ﹤0.01% 2710
2022
Q1 		$572K Buy
3,687
+257
+7% +$51.3K ﹤0.01% 2571
2021
Q4 		$1.02M Hold
3,430
– – ﹤0.01% 2470
2021
Q3 		$1.98M Hold
3,430
– – ﹤0.01% 2057
2021
Q2 		$1.56M Buy
3,430
+2,152
+168% +$1.11M ﹤0.01% 2260
2021
Q1 		$688K Hold
1,278
– – ﹤0.01% 2422
2020
Q4 		$1.13M Buy
+1,278
New +$983K ﹤0.01% 2234

Other funds holding KLRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

Swiss National Bank's KLRS Position: Q4 2023 in Review

Swiss National Bank sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 4,883 shares — an estimated $241K sold.

Swiss National Bank first reported a position in KLRS in Q4 2020 and held it in 12 quarters. The position peaked at $1.98M in Q3 2021. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • Swiss National Bank reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Swiss National Bank sold 4,883 Kalaris Therapeutics shares in Q4 2023, an estimated $241K.
  • Swiss National Bank first reported a position in Kalaris Therapeutics in Q4 2020 and held it in 12 quarters.
  • Swiss National Bank's Kalaris Therapeutics position peaked at $1.98M in Q3 2021.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on Swiss National Bank's 13F filing for Q4 2023, filed 6 Feb 2024.